Big medtech and big pharma are taking a greater role in the funding of medical device start-ups. 2016 was the first year in which the corporate venture arms of the large strategics have put up more than 20% of the cash for early-stage medtech companies, EvaluateMedTech data show (see graph below).
Venture rounds with corporate participation are big – around twice the size of a standard VC round. This is a clear sign of strategics’ determination to get their protégés to an inflection point – sometimes, but by no means always, with an eye to acquiring them themselves.
Anecdotal evidence of both these patterns – more corporate activity, and the greater size of corporate rounds – has been mounting over the past year or two, with last year seeing an eye-popping $175m round for Flatiron Health and $100m for Grail. And, though 2015’s total value of corporate VC rounds was lower, it saw an even bigger round: Adaptive Biotechnologies scored $195m from investors including Illumina, Becton Dickinson and Celgene.
Now the anecdotes are backed with hard data. The total value of rounds with corporate participation hit $869m last year – 22% of all venture investment in the sector.
This figure has increased fairly steadily since 2008, when the financial crisis saw the corporate cash raised nearly halve from 2007’s total of $598m. The figure for total corporate investment did not recover to near-2007 levels until 2011, but since 2013 it has been markedly higher – with the exception of a blip in 2014.
|Year||No of rounds with CVC participation||Total no of rounds||% of rounds with CVC participation||Value of CVC rounds ($m)||Value of all rounds ($bn)||% of value from rounds with CVC participation|
That said, the corporate rounds now make up more than a fifth of total investments only because the overall venture figure has shrunk. Only $3.9bn was pumped into start-ups last year; if this level had remained steady from 2015’s figure of $4.5bn, corporate activity would only make up 19% of the total.
So, despite the increased effort on the part of big medtech and big pharma, the decline in development capital being made available to the medtech sector is such that the gap is still widening.
It has also long been apparent that VCs clustering together into ever-larger rounds is a growing problem, since it limits the number of start-ups that can benefit from early-stage capital (Huge medtech venture rounds mean start-ups starve, January 19, 2016). Corporate activity, it seems, is only exacerbating this situation.
Rounds in which corporate VCs have taken part tend to be around twice that of standard rounds: $26m versus $13m in 2015, and $33m versus $15m last year. This makes sense as a risk-reduction strategy whether the investor’s ultimate aim is to acquire the company or simply to make a return on its investment.
In either scenario the investor will want to get the company to a point where its devices are approved in the US, or at least CE marked. This means piling on the cash right from the start – Grail’s $100m series A last year and Helix Opco’s $100m in seed capital in 2015 are exemplars here.
|Corporate VC rounds are bigger|
|Year||Average size of CVC round ($m)||Average size of all rounds ($m)|
So which companies are putting all this money up? One investor is head and shoulders above the rest: J&J. Its venture arm, Johnson & Johnson Development Corporation (JJDC), has participated in rounds worth an astonishing $1.6bn in the medtech sector over the past decade, more than twice as much as the second-placed company, Medtronic.
Note that this does not mean J&J has itself paid $1.6bn. It is not possible to say precisely how much J&J has invested as the individual contributions of investors within a VC round are vanishingly rarely disclosed.
According to an executive at J&J, JJDC is the oldest corporate venture group in existence, and prides itself on being a leader in investing in medical devices. And, separate from the direct investment the company has a network of incubators called JLABS, another way in which it fosters innovation (J&J looks to external innovation to secure the future, October 14, 2015).
Perhaps the most remarkable of the corporate VCs is not particularly prolific, but it is extremely generous. Illumina has participated in just five rounds in the past decade. But the rounds to which it has contributed are worth a total of $454m, giving an average size of $91m.
Three of the top five corporate investors in medical technologies are conglomerates, and arguably more accurately described as big pharma than big medtech: J&J, Novartis and Roche make 35%, 12% and 23% respectively of their sales from devices or diagnostics. And some of the other prolific investors in device companies, including Pfizer, Novo Nordisk and Debiopharm, have no presence at all in medtech.
|The most prolific corporate VCs in medtech|
|Investor||No of rounds||Total value ($m)*||Avg size ($m)|
|Johnson & Johnson||55||1,683.3||30.6|
|*Total value of rounds in which the investor has participated.|
But even a pure pharma company can benefit from medtech start-ups bringing technologies to market: companion diagnostics or blood glucose sensors are obvious example of such technologies. And quite apart from that, some companies make venture investments without a strategic angle – just like traditional venture funds, some corporates are simply seeking a pay day.